Drugs / GB224
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04179513 | Aug 2019 → Dec 2020 | rheumatoid arthritis | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04178070 | Nov 2017 → Dec 2020 | rheumatoid arthritis | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04178070 ↗ |
| Route | Subcutaneous | “abdominal subcutaneous injection” NCT04178070 ↗ |